MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More

2024-03-25T08:36:57-07:00September 1st, 2019|BluePrint, Evidence, MammaPrint, Other, Validation|

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). Read More

2024-03-25T08:54:30-07:00April 18th, 2019|Evidence, NBRST, Neoadjuvant|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

2024-03-25T08:56:28-07:00March 27th, 2019|BluePrint, Evidence, Other, Validation|

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. AUTHORS: Read More

2024-03-25T09:23:03-07:00November 1st, 2015|BluePrint, Evidence, Other|

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Read More

2024-03-25T10:44:00-07:00August 4th, 2013|Adjuvant, BluePrint, Evidence|

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Read More

2024-03-25T10:51:59-07:00August 15th, 2012|BluePrint, Evidence, Other, Validation|

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. AUTHORS: Read More

2024-03-25T10:54:08-07:00May 1st, 2012|BluePrint, Evidence, Neoadjuvant|
Go to Top